J&J's apalutamide meets in Phase III for non-metastatic CRPC

Newly released data showed apalutamide (JNJ56021927) from Johnson & Johnson (NYSE:JNJ) met the primary endpoint in the Phase III SPARTAN trial to treat

Read the full 236 word article

User Sign In